drugset
Drugs / IPV-Al
last change May 2021 re-read 3 minutes ago

IPV-Al

also known as IPV-Al SSI

Vaccine

Developed for
poliomyelitis
Investigated by
AJ Vaccines A/S · Bill and Melinda Gates Foundation · Larix A/S · Statens Serum Institut · Syneos Health

Trials 2

today NCT04448132 · Ph 4 NCT03032419 · Ph 3
20172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 31 trial · 1 met primary
Phase 3 NCT03032419 Feb → Sep 2017 poliomyelitis Statens Serum Institut Completed Met primary
Phase 41 trial
Phase 4 NCT04448132 Nov 2020 → May 2021 poliomyelitis AJ Vaccines A/S Completed No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2018-03-19 AJ Vaccines A/S AJ Vaccines successfully completes two phase III trials of its new low-dose IPV-Al vaccine ajvaccines.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as IPV-Al ClinicalTrials.gov intervention name — accepted as the source's own label NCT04448132 ↗
1

NCT03032419 ↗
Known as IPV-Al SSI “The trial is a phase III, non-inferiority, observer-blind, randomised, controlled, multicentre clinical trial with 2 parallel groups: IPV-Al SSI (investigational vaccine) and...” NCT03032419 ↗
Modality Vaccine “A dose-sparing inactivated polio vaccine (IPV-Al), obtained by adsorption of inactivated virus to an aluminium hydroxide adjuvant” PMID 31703934 ↗ Nov 2019
Route Intramuscular “IPV-Al contains the reduced dose of IPV to be administered intramuscularly to the anterolateral aspect of the right thigh” NCT03032419 ↗